Role of Serotonin in Regulation of the Pituitary-Adrenocortical Axis in Rats

The possible dopaminergic properties of the central serotonergic agonist quipazine was examined using plasma prolactin release as a model to determine whether quipazine exerts an agonist effect on only serotonin receptors or on dopamine receptors as well. Drugs acting on two different receptors have only an additive effect on the same parameter while different drugs acting on the same receptor exert a synergistic effect. Therefore we determined whether combining quipazine with haloperidol, which has no effect on serotonin receptors, would produce a synergistic or only an additive effect on prolactin release, relative to the release induced by quipazine alone. A distinct synergism was produced, suggesting that quipazine acts on both DA and 5-HT receptors. Moreover, the model used may be useful for distinguishing whether a given drug acts on one or two receptors concurrently.

Quipazine

Serotonin Agonist

Endogenous agonist

10.3109/00207458308985875

Cite

Citations (2)

Functional change in the 5-HT presynaptic receptor in spinal cord of aged rats

Neurobiology of Aging (1989)

Ricardo Murphy Frank P. Zemlan

Quipazine

Serotonin Agonist

5-HT1A receptor

8-OH-DPAT

10.1016/s0197-4580(89)80016-8

Cite

Citations (16)

The Effect of Quipazine, A Serotonin Receptor Agonist, on Serum Corticosterone Concentration in Rats

Endocrine Research Communications (1978)

Ray W. Fuller Harold D. Snoddy James A. Clemens

Quipazine, a serotonin receptor agonist, increased serum corticosterone within 30 min after its i.p. injection (at 10 mg/kg) into rats; the effect persisted at 1 and 2 hrs, but not at 4 hrs. Elevation of serum corticosterone did not occur with a 1.25 mg/kg dose of quipazine but was dose-related over a 2.5-20 mg/kg dose range. The effect of quipazine was completely prevented by methergoline, a serotonin receptor antagonist. The effect of quipazine was present in rats pretreated with 5,7-dihydroxytryptamine to destroy serotonin nerves and was not enhanced (as was the effect of L-5-hydroxytryptophan) by fluoxetine pretreatment. These data are compatible with the idea that quipazine increases serum corticosterone as a consequence of direct stimulation of serotonin receptors in brain.

Quipazine

Serotonin Agonist

Corticosterone

10.3109/07435807809089015

Cite

Citations (40)

Serotonin-like actions of quipazine on the central nervous system

European Journal of Pharmacology (1973)

Rodolfo Rodríguez J.A. Rojas-Ramírez RenéRaúl Drucker-Colín

Quipazine

Serotonin Agonist

Metergoline